Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
CEINGE Advanced Biotechnologies, 80145 Naples, Italy.
Int J Mol Sci. 2021 May 27;22(11):5742. doi: 10.3390/ijms22115742.
Mitochondrial Cardiomyopathy (MCM) is a common manifestation of multi-organ Mitochondrial Diseases (MDs), occasionally present in non-syndromic cases. Diagnosis of MCM is complex because of wide clinical and genetic heterogeneity and requires medical, laboratory, and neuroimaging investigations. Currently, the molecular screening for MCM is fundamental part of MDs management and allows achieving the definitive diagnosis. In this article, we review the current genetic knowledge associated with MDs, focusing on diagnosis of MCM and MDs showing cardiac involvement. We searched for publications on mitochondrial and nuclear genes involved in MCM, mainly focusing on genetic screening based on targeted gene panels for the molecular diagnosis of the MCM, by using Next Generation Sequencing. Here we report twelve case reports, four case-control studies, eleven retrospective studies, and two prospective studies, for a total of twenty-nine papers concerning the evaluation of cardiac manifestations in mitochondrial diseases. From the analysis of published causal mutations, we identified 130 genes to be associated with mitochondrial heart diseases. A large proportion of these genes (34.3%) encode for key proteins involved in the oxidative phosphorylation system (OXPHOS), either as directly OXPHOS subunits (22.8%), and as OXPHOS assembly factors (11.5%). Mutations in several mitochondrial tRNA genes have been also reported in multi-organ or isolated MCM (15.3%). This review highlights the main disease-genes, identified by extensive genetic analysis, which could be included as target genes in next generation panels for the molecular diagnosis of patients with clinical suspect of mitochondrial cardiomyopathies.
线粒体心肌病(MCM)是多器官线粒体疾病(MDs)的常见表现形式,偶尔在非综合征病例中出现。由于广泛的临床和遗传异质性,MCM 的诊断较为复杂,需要进行医学、实验室和神经影像学检查。目前,MCM 的分子筛查是 MDs 管理的重要组成部分,可以实现明确诊断。本文综述了与 MDs 相关的当前遗传知识,重点介绍了 MCM 和伴有心脏受累的 MDs 的诊断。我们搜索了与 MCM 相关的线粒体和核基因的出版物,主要关注基于靶向基因面板的遗传筛查,以用于 MCM 的分子诊断,采用下一代测序技术。在此,我们报告了 12 例病例报告、4 例病例对照研究、11 例回顾性研究和 2 例前瞻性研究,共 29 篇关于线粒体疾病心脏表现评估的论文。通过对已发表的致病突变进行分析,我们确定了 130 个与线粒体心脏病相关的基因。这些基因中的很大一部分(34.3%)编码参与氧化磷酸化系统(OXPHOS)的关键蛋白,要么作为直接的 OXPHOS 亚基(22.8%),要么作为 OXPHOS 组装因子(11.5%)。几个线粒体 tRNA 基因的突变也已在多器官或孤立的 MCM 中报道(15.3%)。本综述强调了通过广泛的遗传分析确定的主要疾病基因,这些基因可以作为下一代基因面板的目标基因,用于对有临床疑似线粒体心肌病的患者进行分子诊断。